Checkpoint Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accounts Payable and Accrued Expenses

9 Months Ended

Sep. 30, 2020

Note 7 - Accounts Payable and Accrued Expenses

At September 30, 2020 and December 31, 2019, accounts payable and accrued expenses consisted of the following ($ in thousands):


	September 30,		December 31,
	2020		2019
Accounts payable	$	2,467	$	3,079
Accrued compensation		326		414
Research and development		2,289		3,496
Other		583		268
Total accounts payable and accrued expenses	$	5,665	$	7,257